Sarcoma
M. Voermans, M. Bui, MD, PhD, E. Conrad, G. D'Amato, MD, J. Goodwin, A. O'Driscoll, MBA, MPA, R. Ratan, MD, MEd, D. Reinke, MS, NP, MBA, E. Peregrine Antalis, MPH, PhD
The authors propose potential solutions to the challenges faced by patients with Epithelioid Sarcoma.
Although not the most common of
cancers, pediatric and adult sarcomas
affect a significant proportion
of patients, and managing these malignancies
first requires understanding
them, according to Paula Sanborn, BSN,
RN.
On December 3, 2019, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to the biopharmaceutical company Adaptimmune Therapeutics for ADP-A2M4 for the treatment of synovial sarcoma. Earlier this year, the FDA granted Orphan Drug designation to the agent for the treatment of soft tissue sarcomas.
Results 1 - 3 of 3
